Recent Security Class Actions

HUMANIGEN INC (US TRADING VENUE: HGEN)

26 Days left to seek lead plaintiff status.

Company Name:HUMANIGEN INC
Stock Symbol:US TRADING VENUE: HGEN
Class Period Start:05/28/2021
Class Period End (inclusive):07/12/2022
Filing Deadline:10/25/2022

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) lenzilumab was less effective in treating hospitalized COVID-19 patients than Defendants had represented; (ii) as a result, the FDA was unlikely to approve the lenzilumab EUA and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab’s clinical and commercial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

HUMANIGEN INC (US TRADING VENUE: HGEN) Claim Form

Name(Required)
Address
Consent(Required)
This field is for validation purposes and should be left unchanged.